{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    4,
    5,
    6,
    59
  ],
  "modelUsed": "claude-opus-4-5",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_b",
        "affectedSection": "Section 1.1 Synopsis / Section 3 Objectives and Endpoints",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Key secondary objective at 20 weeks modified from by dose to pooled dose analysis for 10 mg and 15 mg doses"
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_b",
        "affectedSection": "Section 1.1 Synopsis / Section 3 Objectives and Endpoints",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Key secondary objective at 72 weeks modified - added endpoint for ≥20% body weight reduction from randomization"
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_b",
        "affectedSection": "Section 1.1 Synopsis / Section 3 Objectives and Endpoints",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "SF-36v2 acute form Physical Functioning domain score objective moved from by dose to pooled dose analysis"
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_b",
        "affectedSection": "Section 4.1.2.3",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added guidance for definition of incident diabetes, retesting, confirmation, recording, and adjudication"
      },
      {
        "id": "impact_5",
        "amendmentId": "amend_b",
        "affectedSection": "Section 6.6.1 Tirzepatide",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added allowance for dose modification for management of participants with perceived excessive weight loss during additional 2-year treatment period"
      },
      {
        "id": "impact_6",
        "amendmentId": "amend_b",
        "affectedSection": "Section 6.6.3 Management of Participants with Perceived Excessive Weight Loss",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added new subsection for managing participants with perceived excessive weight loss during additional 2-year treatment period"
      },
      {
        "id": "impact_7",
        "amendmentId": "amend_b",
        "affectedSection": "Section 7.2 Participant Discontinuation/Withdrawal from the Study",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added requirement for female participants to be withdrawn if they become pregnant"
      },
      {
        "id": "impact_8",
        "amendmentId": "amend_b",
        "affectedSection": "Section 9.1 Statistical Hypotheses",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated to reflect changes in key secondary objectives and endpoints"
      },
      {
        "id": "impact_9",
        "amendmentId": "amend_b",
        "affectedSection": "Section 9.4.3.1 Primary Analyses",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated information on estimands and related analyses to address FDA feedback"
      },
      {
        "id": "impact_10",
        "amendmentId": "amend_b",
        "affectedSection": "Section 9.4.3.2 Key Secondary Analyses",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated to reflect changes in key objectives and endpoints"
      },
      {
        "id": "impact_11",
        "amendmentId": "amend_b",
        "affectedSection": "Section 9.4.4.4.2 Events Related to Potential Abuse Liability",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated abuse liability event identification to use narrow terms from SMQ of Drug abuse and dependence"
      },
      {
        "id": "impact_12",
        "amendmentId": "amend_b",
        "affectedSection": "Section 10.1.4 Committee Structure",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added wording for adjudication of incident diabetes events with cross-reference to Section 4.1.2.3"
      },
      {
        "id": "impact_13",
        "amendmentId": "amend_b",
        "affectedSection": "Section 10.4 Appendix 4 Contraceptive Guidance and Collection of Pregnancy Information",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Modified to indicate pregnant participants will discontinue study intervention and be withdrawn from study"
      },
      {
        "id": "impact_14",
        "amendmentId": "amend_b",
        "affectedSection": "Section 10.7 Appendix 7 Protocol GPHK Standardized Protocols",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added note that venous cannula may not be required for 2-hour OGTT repeat to confirm diabetes diagnosis"
      },
      {
        "id": "impact_15",
        "amendmentId": "amend_b",
        "affectedSection": "Throughout",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Standardized terminology for additional 2-year treatment period for participants with prediabetes at randomization"
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_b",
        "reasonText": "Update key study objectives and endpoints, clarify incident diabetes definition, add guidance for dose modification during additional 2-year treatment period, and update statistical analyses to align with SAP",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_b",
        "reasonText": "Analysis of pooled data from participants on different tirzepatide doses is more appropriate as participants randomized to the 15-mg dose will not be exposed to that dose until after Week 20",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_b",
        "reasonText": "To better inform clinical decisions in management of people living with obesity",
        "category": "Efficacy",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "amend_b",
        "reasonText": "To support patient management and retention in the additional 2-year treatment period",
        "category": "Operational",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_5",
        "amendmentId": "amend_b",
        "reasonText": "To address and align with FDA feedback",
        "category": "Regulatory",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_6",
        "amendmentId": "amend_b",
        "reasonText": "Based on mechanism of action of tirzepatide, anticipated gastrointestinal adverse events, and low likelihood for abuse potential/psychoactive effects, it is reasonable to narrow the list of abuse terms used",
        "category": "Safety",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_7",
        "amendmentId": "amend_b",
        "reasonText": "For clarity in participant management",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_8",
        "amendmentId": "amend_b",
        "reasonText": "For clarity and consistency",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_b",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "1.1/3",
        "beforeText": "Key secondary objective at 20 weeks by dose analysis",
        "afterText": "Key secondary objective at 20 weeks pooled dose analysis reflecting pooled 10 mg and 15 mg doses",
        "summary": "Changed 20-week key secondary objective from by dose to pooled dose analysis"
      },
      {
        "id": "change_2",
        "amendmentId": "amend_b",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "1.1/3",
        "afterText": "≥20% body weight reduction from randomization",
        "summary": "Added new endpoint for ≥20% body weight reduction at 72 weeks"
      },
      {
        "id": "change_3",
        "amendmentId": "amend_b",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "1.1/3",
        "beforeText": "SF-36v2 acute form Physical Functioning domain score for 10 mg and 15 mg separately in Key secondary at 72 weeks by dose analysis",
        "afterText": "SF-36v2 acute form Physical Functioning domain score moved to Key secondary at 72 weeks pooled dose analysis",
        "summary": "Moved SF-36v2 Physical Functioning objective from by dose to pooled dose analysis"
      },
      {
        "id": "change_4",
        "amendmentId": "amend_b",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "4.1.2.3",
        "afterText": "Guidance for retesting, confirmation, recording, and adjudication of incident diabetes",
        "summary": "Added comprehensive guidance for incident diabetes definition and management"
      },
      {
        "id": "change_5",
        "amendmentId": "amend_b",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "6.6.1",
        "afterText": "Sentence allowing dose modification for management of participants with perceived excessive weight loss during the additional 2-year treatment period for participants with prediabetes at randomization",
        "summary": "Added allowance for dose modification for excessive weight loss management"
      },
      {
        "id": "change_6",
        "amendmentId": "amend_b",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "6.6.3",
        "afterText": "New subsection containing information for managing participants with perceived excessive weight loss during the additional 2-year treatment period for participants with prediabetes at randomization",
        "summary": "Added new subsection for managing excessive weight loss"
      },
      {
        "id": "change_7",
        "amendmentId": "amend_b",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "7.2",
        "afterText": "Female participants will be withdrawn from the study if the participant becomes pregnant",
        "summary": "Added bullet point requiring withdrawal of pregnant participants"
      },
      {
        "id": "change_8",
        "amendmentId": "amend_b",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "9.4.3.1",
        "afterText": "Updated information on estimands and related analyses",
        "summary": "Updated primary analyses to address FDA feedback on estimands"
      },
      {
        "id": "change_9",
        "amendmentId": "amend_b",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "9.4.4.4.2",
        "beforeText": "Previous abuse liability event identification terms",
        "afterText": "To identify AE terms suggestive of potential abuse liability, narrow terms from SMQ of Drug abuse and dependence (20000101) will be used",
        "summary": "Narrowed abuse liability event identification to specific SMQ terms"
      },
      {
        "id": "change_10",
        "amendmentId": "amend_b",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "10.4",
        "beforeText": "If a study participant becomes pregnant, the participant will discontinue study intervention",
        "afterText": "If a study participant becomes pregnant, the participant will discontinue study intervention and will be withdrawn from the study",
        "summary": "Clarified that pregnant participants must both discontinue intervention and withdraw from study"
      },
      {
        "id": "change_11",
        "amendmentId": "amend_b",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "10.7",
        "afterText": "Note stating that placement of a venous cannula may not be required when a 2-hour OGTT is repeated to confirm the diagnosis of diabetes during the study, and only samples at 0 and 120 minutes for glucose measurement will be collected",
        "summary": "Added note clarifying OGTT procedure for diabetes confirmation"
      },
      {
        "id": "change_12",
        "amendmentId": "amend_b",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "Throughout",
        "beforeText": "Various inconsistent terms for study period following primary outcome at Visit 21 (Week 72)",
        "afterText": "Additional 2-year treatment period for participants with prediabetes at randomization",
        "summary": "Standardized terminology for the additional 2-year treatment period"
      }
    ],
    "summary": {
      "impactCount": 15,
      "reasonCount": 8,
      "changeCount": 12
    }
  }
}